These cancer studies use anti-CD74-based antibody-drug conjugates to increase drug uptake or monoclonal antibodies against MIF or CD74 in cancers, including metastatic colon cancer, B-cell lymphoma, and other solid malignancies. This evidence concerns the gene CD74 and B-cell non-Hodgkin lymphoma.